Rosetta Genomics is a leading molecular diagnostics company advancing minimally-invasive molecular tests based on its proprietary microRNAs, and platform technologies. Following the launch of three cancer tests in the beginning of 2009, the Company is now working to develop additional cancer tests which are expected to be commercialized within the next two years.
January 13, 2009
Rosetta Genomics announces issuance of three U.S. patents...More
January 13, 2009
Rosetta Genomics fortifies patent position with human allowance of claims covering human microRNAs miR-21 and hcmv-miR-UL112...More
April 17-21 - AACR 101st Annual Meeting. Washington D.C.More
March 22-24 - MicroRNA in Human Disease and Development. Camebridge, MA.More
